StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — Kush Bohra

BUYEmcure Pharmaceuticals Limited

byKush BohraHorizon: NA (inferred Swing (≤2wk))18 Sept 2026via NDTV Profit

Entry₹2,070Inferred
Target₹2,200
Total upside +6.28%
Stop loss₹1,900-8.21% risk
CMP₹2,003.81d ago
Active-3.20%+9.79%upside left 11d left
Follow Kush Bohra for new calls(36% target hit, 106 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 1 other Swing call on EMCURESee 271 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 20 Sept, 5:06 am IST
6 supporting2 neutral0 opposing
Supports the BUY call (6)

MACD above its signal line — bullish momentum

Technicals · macd·19 Sept · today

Past week's volume 2.6× the 30-day average

Technicals · volume·18 Sept · yesterday

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·10 Sept · 1w ago

Emcure Pharma: Here's Why ICICI Direct Calls It A High-Conviction 'Buy'

NewsNdtv-Profit·7 Sept · 2w ago

(opens in new tab)

Broker’s call: Emcure Pharma (Buy)

NewsHbl·4 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (2)

Market Trading Guide: Acme Solar, Bharat Dynamics among 5 stock recommendations for Wednesday

NewsEt-Markets·15 Sept · 4d ago

(opens in new tab)

Market Trading Guide: Emcure Pharma among 2 stock recommendations for Monday

NewsEt-Markets·6 Sept · 2w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.